References
- Wolf PA, Mitchell JB, Baker CS et al. Mortality and hospital costs associated with atrial fibrillation. Circulation 92, 1–40 (1995).
- Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am. J. Cardiol. 84(9A), 131R–138R (1999).
- Hohnloser SH, Crijns HJ, van Eickels M et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360(7), 668–678 (2009).
- Connolly SJ, Camm AJ, Halperin JL et al.; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365(24), 2268–2276 (2011).
- Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J. 24(16), 1481–1487 (2003).
- Singh BN, Connolly SJ, Crijns HJ et al.; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357(10), 987–999 (2007).
- Davy JM, Herold M, Hoglund C et al.; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am. Heart J. 156(3), 527.e1–527.e9 (2008).
- Køber L, Torp-Pedersen C, McMurray JJ et al.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358(25), 2678–2687 (2008).
- Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. 21(6), 597–605 (2010).
- Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today 42(2), 75–86 (2006).
- Wyse DG, Waldo AL, DiMarco JP et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347(23), 1825–1833 (2002).
- Salam AM. Rate control versus rhythm control for the management of atrial fibrillation: the verdict of the AFFIRM trial. Expert Opin. Investig. Drugs 12(7), 1231–1237 (2003).
Websites
- US FDA. FDA Drug Safety Communication: Review update of Multaq® (dronedarone) and increased risk of death and serious cardiovascular adverse events. www.fda.gov/Drugs/DrugSafety/ucm283933.htm (Accessed 10 July 2012)
- EMA. Revised dronedarone guidelines/restrictions. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/09/WC500112800.pdf (Accessed 10 July 2012)